Searched for
BIOCON BIOSIMILARS PERFORMANCE
Biocon reports 63% YoY fall in Q4 profit, final dividend of Rs. 0.50 recommendedBiocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges im...- Biocon Q4 Results: Net profit down 57% at Rs 198.6 croreBiocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...
- Biocon plans $150-million capex in two yearsBiocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 mi...
- Biocon shares in focus after successful results of Yesintek in Phase 3Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the last six month...
- Biocon Q3 Results: PAT at Rs 660 crore vs Rs 42-crore loss a year agoThe company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' branded...
- Biocon denies plans to sell $1.5 billion generic API businessBiocon API business: Biocon has refuted claims of considering the sale of its generic active pharmaceutical ingredient (API) business, valu...
- On track to integrate major part of Viatris'' acquired biosimilars biz this fiscal: Kiran Mazumdar-ShawBiocon Biologics is set to integrate a major portion of the biosimilars business acquired from Viatris in the current fiscal year, accordin...
- Biocon Q4 Results: Net profit jumps 31% on strong biosimilar business growthIndian biopharmaceutical company Biocon posted a 31% year-on-year rise in Q4 FY23 net profit, at INR313 crore ($41.9m), driven by successfu...
- Biocon completes $3.34 billion acquisition of Viatris's biosimilar businessTo fund the upfront payment, Biocon Biologics has secured $1.2 billion of Sustainability Linked Loan (SLL). The balance has been funded thr...
- Biocon Q4 Results: Profit declines 4% to Rs 283 crConsolidated revenue from operations in the fourth quarter stood at Rs 2,408.8 crore as against Rs 1,842.1 crore in the year-ago period, it...
- Biocon Biologics set to reap biosimilar insulin glargine opportunity in USDrugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and pr...
- Biocon Q3 Results: Net profit rises 11% YoY to Rs 187 croreThe earnings before interest, tax depreciation and amortisation (EBITDA) rose 25% YoY to Rs 537 crore. The EBITDA margins for the third qua...
- Biocon Q2 Results: Profit dips 18% to Rs 138 croreThe country’s largest biopharmaceutical company’s net profits before exceptional items grew by 11% to Rs 188 crore in the quarter, it repor...
- Kiran Mazumdar Shaw on how biologics and small molecules drove Biocon profit in Q1Biologics is the segment to watch as we have invested in it and it is delivering for us.
- Biocon reports 64% jump in Q4 net riding on biologicsBiocon reported a 64 per cent jump in its net profit for the quarter ending March 2019.
- Biocon has little room to slip up after strong 2016At the end of 2015, 70% of analysts tracking the Biocon stock had a buy recommendation on it. Data from Bloomberg show that this number has...
- Biocon Q1 net up 17% at Rs 147 croreTotal revenue of the company rose to Rs 952 crore for the first quarter, as compared to Rs 857 crore during the same period of correspondin...
- Biocon Q2 net profit jumps 3-fold at Rs 306 croreThe consolidated revenue of Biocon was up by 11.38 per cent at Rs 861 crore during the quarter compared to Rs 773 crore in the year-ago per...
- Biocon logs smart recovery in fourth quarterAfter the divestment of Axicorp and the snapping of its biosimilar insulin deal with Pfizer, the company was expected to post a subdued per...
- Biocon: Parting ways with Pfizer may hurt company in long runWith the snapping of ties, the Indian biotech company has limited options for growth of its insulin especially in regulated markets.
Load More
